Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Prudential Financial Inc.

Prudential Financial Inc. increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 138.5% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 33,855 shares of the specialty pharmaceutical company’s stock after purchasing an additional 19,660 shares during the quarter. Prudential Financial Inc.’s holdings in Jazz Pharmaceuticals were worth $3,593,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JAZZ. American Century Companies Inc. increased its stake in shares of Jazz Pharmaceuticals by 34.5% during the 2nd quarter. American Century Companies Inc. now owns 253,030 shares of the specialty pharmaceutical company’s stock valued at $26,852,000 after acquiring an additional 64,968 shares during the last quarter. Rhumbline Advisers grew its holdings in Jazz Pharmaceuticals by 0.3% in the second quarter. Rhumbline Advisers now owns 165,012 shares of the specialty pharmaceutical company’s stock valued at $17,511,000 after purchasing an additional 456 shares during the period. Legal & General Group Plc increased its position in Jazz Pharmaceuticals by 11.2% during the second quarter. Legal & General Group Plc now owns 185,824 shares of the specialty pharmaceutical company’s stock worth $19,720,000 after purchasing an additional 18,675 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Jazz Pharmaceuticals by 3.6% during the second quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company’s stock worth $182,664,000 after purchasing an additional 59,252 shares during the period. Finally, Ensign Peak Advisors Inc boosted its holdings in shares of Jazz Pharmaceuticals by 17.9% in the 2nd quarter. Ensign Peak Advisors Inc now owns 28,435 shares of the specialty pharmaceutical company’s stock valued at $3,018,000 after purchasing an additional 4,316 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $166.71 on Wednesday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $182.99. The company has a market capitalization of $10.13 billion, a price-to-earnings ratio of -24.77, a PEG ratio of 8.49 and a beta of 0.30. The business has a 50-day moving average of $145.46 and a 200-day moving average of $126.14.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Bank of America boosted their price target on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Morgan Stanley upped their price target on Jazz Pharmaceuticals from $185.00 to $205.00 and gave the stock an “overweight” rating in a research note on Monday, November 17th. Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Finally, The Goldman Sachs Group boosted their target price on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a report on Friday, August 29th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.67.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 5,319 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $182.06, for a total value of $968,377.14. Following the completion of the transaction, the chief accounting officer directly owned 7,012 shares in the company, valued at approximately $1,276,604.72. This represents a 43.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Heather Ann Mcsharry sold 3,415 shares of the firm’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $177.78, for a total transaction of $607,118.70. Following the sale, the director directly owned 20,449 shares of the company’s stock, valued at approximately $3,635,423.22. The trade was a 14.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 122,393 shares of company stock worth $21,568,254 over the last 90 days. 4.30% of the stock is owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.